News Mirum puts Hepcludex in its sights with hep D readout Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
News Roche culls myostatin candidate from obesity pipeline Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
News Wnt drug gives MSD first eye disease win after EyeBio deal MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
R&D Sponsored Turning recruitment potential into enrolment reality In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs
News Kyverna builds case for CAR-T in stiff person syndrome Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.
News Roche, Viking, and Syntis showcase obesity drug candidates A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.